JP2020511946A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020511946A5 JP2020511946A5 JP2019533076A JP2019533076A JP2020511946A5 JP 2020511946 A5 JP2020511946 A5 JP 2020511946A5 JP 2019533076 A JP2019533076 A JP 2019533076A JP 2019533076 A JP2019533076 A JP 2019533076A JP 2020511946 A5 JP2020511946 A5 JP 2020511946A5
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- seq
- sequence
- gremlin
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102100038367 Gremlin-1 Human genes 0.000 claims 7
- 101710169781 Gremlin-1 Proteins 0.000 claims 7
- 239000008194 pharmaceutical composition Substances 0.000 claims 3
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 239000000178 monomer Substances 0.000 claims 2
- 102000040430 polynucleotide Human genes 0.000 claims 2
- 108091033319 polynucleotide Proteins 0.000 claims 2
- 239000002157 polynucleotide Substances 0.000 claims 2
- 108010032595 Antibody Binding Sites Proteins 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 1
- 241001465754 Metazoa Species 0.000 claims 1
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 claims 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 claims 1
- 239000002671 adjuvant Substances 0.000 claims 1
- 230000033115 angiogenesis Effects 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 239000013604 expression vector Substances 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 230000002265 prevention Effects 0.000 claims 1
- 201000002793 renal fibrosis Diseases 0.000 claims 1
- 238000003571 reporter gene assay Methods 0.000 claims 1
- 239000013598 vector Substances 0.000 claims 1
- 238000002424 x-ray crystallography Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1621635.0 | 2016-12-19 | ||
| GBGB1621635.0A GB201621635D0 (en) | 2016-12-19 | 2016-12-19 | Crystal structure |
| PCT/EP2017/083650 WO2018115017A2 (en) | 2016-12-19 | 2017-12-19 | Gremlin-1 crystal structure and inhibitory antibody |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020511946A JP2020511946A (ja) | 2020-04-23 |
| JP2020511946A5 true JP2020511946A5 (enExample) | 2021-01-14 |
| JP7097364B2 JP7097364B2 (ja) | 2022-07-07 |
Family
ID=58284547
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019533076A Active JP7097364B2 (ja) | 2016-12-19 | 2017-12-19 | グレムリン－１の結晶構造及び阻害抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (3) | US10947304B2 (enExample) |
| EP (1) | EP3555129A2 (enExample) |
| JP (1) | JP7097364B2 (enExample) |
| KR (1) | KR102557216B1 (enExample) |
| CN (1) | CN110099924B (enExample) |
| AR (1) | AR110394A1 (enExample) |
| AU (1) | AU2017384471B2 (enExample) |
| BR (1) | BR112019010903A2 (enExample) |
| CA (1) | CA3045742A1 (enExample) |
| CL (1) | CL2019001715A1 (enExample) |
| CO (1) | CO2019006073A2 (enExample) |
| EA (1) | EA201991511A1 (enExample) |
| EC (1) | ECSP19051912A (enExample) |
| GB (1) | GB201621635D0 (enExample) |
| IL (1) | IL267287A (enExample) |
| MA (1) | MA47669A (enExample) |
| MX (1) | MX2019006630A (enExample) |
| MY (1) | MY202395A (enExample) |
| PE (1) | PE20191542A1 (enExample) |
| PH (1) | PH12019501319A1 (enExample) |
| RU (1) | RU2769285C2 (enExample) |
| TN (1) | TN2019000188A1 (enExample) |
| TW (1) | TWI787223B (enExample) |
| UA (1) | UA126025C2 (enExample) |
| UY (1) | UY37528A (enExample) |
| WO (1) | WO2018115017A2 (enExample) |
| ZA (1) | ZA201903810B (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| GB201802486D0 (en) * | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| EP3806898B1 (en) * | 2018-06-18 | 2025-10-08 | UCB Biopharma SRL | Gremlin-1 antagonist for use in the treatment of cancer |
| CN116848135A (zh) * | 2021-01-18 | 2023-10-03 | 苏州创胜医药集团有限公司 | 新颖的抗gremlin1抗体 |
| AU2022233762A1 (en) * | 2021-03-11 | 2023-10-05 | Shanghai Jiao Tong University | Method of treating diseases using gremlin1 antagonists |
| GB202205203D0 (en) | 2022-04-08 | 2022-05-25 | UCB Biopharma SRL | Combination with inhibitor |
| GB202205200D0 (en) | 2022-04-08 | 2022-05-25 | Ucb Biopharma Sprl | Combination with chemotherapy |
| CA3243581A1 (en) * | 2022-04-20 | 2023-10-26 | Kantonsspital St. Gallen | ANTIBODIES OR ANTIGEN-BINDING FRAGMENTS THAT BIND PANSPECIFICALLY TO GREMLIN-1 AND GREMLIN-2 AND RELATED USES |
| WO2024258870A2 (en) | 2023-06-12 | 2024-12-19 | Amgen Inc. | Lymphotoxin beta receptor agonist binding proteins |
Family Cites Families (56)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8422238D0 (en) | 1984-09-03 | 1984-10-10 | Neuberger M S | Chimeric proteins |
| DK336987D0 (da) | 1987-07-01 | 1987-07-01 | Novo Industri As | Immobiliseringsmetode |
| GB8719042D0 (en) | 1987-08-12 | 1987-09-16 | Parker D | Conjugate compounds |
| GB8720833D0 (en) | 1987-09-04 | 1987-10-14 | Celltech Ltd | Recombinant dna product |
| DE768377T1 (de) | 1988-09-02 | 1998-01-02 | Dyax Corp | Herstellung und Auswahl von Rekombinantproteinen mit verschiedenen Bindestellen |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| GB8907617D0 (en) | 1989-04-05 | 1989-05-17 | Celltech Ltd | Drug delivery system |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| WO1991010737A1 (en) | 1990-01-11 | 1991-07-25 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
| US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
| ATE139258T1 (de) | 1990-01-12 | 1996-06-15 | Cell Genesys Inc | Erzeugung xenogener antikörper |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| CA2090126C (en) | 1990-08-02 | 2002-10-22 | John W. Schrader | Methods for the production of proteins with a desired function |
| AU8507191A (en) | 1990-08-29 | 1992-03-30 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5770429A (en) | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
| CA2095633C (en) | 1990-12-03 | 2003-02-04 | Lisa J. Garrard | Enrichment method for variant proteins with altered binding properties |
| WO1992018619A1 (en) | 1991-04-10 | 1992-10-29 | The Scripps Research Institute | Heterodimeric receptor libraries using phagemids |
| GB9112536D0 (en) | 1991-06-11 | 1991-07-31 | Celltech Ltd | Chemical compounds |
| GB9113120D0 (en) | 1991-06-18 | 1991-08-07 | Kodak Ltd | Photographic processing apparatus |
| GB9120467D0 (en) | 1991-09-26 | 1991-11-06 | Celltech Ltd | Anti-hmfg antibodies and process for their production |
| ES2341666T3 (es) | 1991-12-02 | 2010-06-24 | Medimmune Limited | Produccion de autoanticuerpos de repertorios de segmentos de anticue rpos expresados en la superficie de fagos. |
| US5733743A (en) | 1992-03-24 | 1998-03-31 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| EP0733070A1 (en) | 1993-12-08 | 1996-09-25 | Genzyme Corporation | Process for generating specific antibodies |
| EP1231268B1 (en) | 1994-01-31 | 2005-07-27 | Trustees Of Boston University | Polyclonal antibody libraries |
| FR2716640B1 (fr) | 1994-02-28 | 1996-05-03 | Procedes Machines Speciales | Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion. |
| US5516637A (en) | 1994-06-10 | 1996-05-14 | Dade International Inc. | Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage |
| JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
| GB9625640D0 (en) | 1996-12-10 | 1997-01-29 | Celltech Therapeutics Ltd | Biological products |
| EP1357828A2 (en) | 2001-01-12 | 2003-11-05 | University of Medicine and Dentistry of New Jersey | Bone morphogenetic protein-2 in the treatment and diagnosis of cancer |
| US6908963B2 (en) | 2001-10-09 | 2005-06-21 | Nektar Therapeutics Al, Corporation | Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith |
| PT1570267E (pt) | 2002-12-03 | 2012-01-03 | Ucb Pharma Sa | Ensaio para a identificação de células produtoras de anticorpos |
| GB0312481D0 (en) | 2003-05-30 | 2003-07-09 | Celltech R&D Ltd | Antibodies |
| GB0315450D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| GB0315457D0 (en) | 2003-07-01 | 2003-08-06 | Celltech R&D Ltd | Biological products |
| US7989594B2 (en) | 2003-07-01 | 2011-08-02 | Celltech R & D Limited | Modified antibody fab fragments |
| EP2824190A1 (en) | 2003-09-09 | 2015-01-14 | Integrigen, Inc. | Methods and compositions for generation of germline human antibody genes |
| EP1571159A1 (en) | 2004-03-04 | 2005-09-07 | Bayerische Julius-Maximilians-Universität Würzburg | Mutein of a bone morphogenetic protein and use thereof |
| GB0411186D0 (en) | 2004-05-19 | 2004-06-23 | Celltech R&D Ltd | Biological products |
| GB0412181D0 (en) | 2004-06-01 | 2004-06-30 | Celltech R&D Ltd | Biological products |
| US20090203041A1 (en) | 2006-04-21 | 2009-08-13 | Wei Shi | Bmp4 inhibitors |
| GB0619291D0 (en) | 2006-09-29 | 2006-11-08 | Ucb Sa | Altered antibodies |
| US8383349B2 (en) | 2007-03-16 | 2013-02-26 | The Board Of Trustees Of The Leland Stanford Junior University | Bone morphogenetic protein antagonist and uses thereof |
| CA2700714C (en) | 2007-09-26 | 2018-09-11 | Ucb Pharma S.A. | Dual specificity antibody fusions |
| EP2826790B1 (en) * | 2012-03-15 | 2019-02-13 | SNU R&DB Foundation | Anti-gremlin-1 antibody |
| EP2970448B1 (en) * | 2013-03-14 | 2021-11-03 | Regeneron Pharmaceuticals, Inc. | Human antibodies to grem 1 |
| GB201621635D0 (en) | 2016-12-19 | 2017-02-01 | Ucb Biopharma Sprl | Crystal structure |
| GB201802486D0 (en) | 2018-02-15 | 2018-04-04 | Ucb Biopharma Sprl | Methods |
| EP3806898B1 (en) | 2018-06-18 | 2025-10-08 | UCB Biopharma SRL | Gremlin-1 antagonist for use in the treatment of cancer |
-
2016
- 2016-12-19 GB GBGB1621635.0A patent/GB201621635D0/en not_active Ceased
-
2017
- 2017-12-19 TN TNP/2019/000188A patent/TN2019000188A1/en unknown
- 2017-12-19 CN CN201780079116.0A patent/CN110099924B/zh active Active
- 2017-12-19 KR KR1020197020545A patent/KR102557216B1/ko active Active
- 2017-12-19 PE PE2019001251A patent/PE20191542A1/es unknown
- 2017-12-19 EA EA201991511A patent/EA201991511A1/ru unknown
- 2017-12-19 UY UY0001037528A patent/UY37528A/es unknown
- 2017-12-19 EP EP17825499.1A patent/EP3555129A2/en active Pending
- 2017-12-19 TW TW106144629A patent/TWI787223B/zh active
- 2017-12-19 WO PCT/EP2017/083650 patent/WO2018115017A2/en not_active Ceased
- 2017-12-19 JP JP2019533076A patent/JP7097364B2/ja active Active
- 2017-12-19 US US16/470,996 patent/US10947304B2/en active Active
- 2017-12-19 CA CA3045742A patent/CA3045742A1/en active Pending
- 2017-12-19 MX MX2019006630A patent/MX2019006630A/es unknown
- 2017-12-19 MA MA047669A patent/MA47669A/fr unknown
- 2017-12-19 MY MYPI2019003411A patent/MY202395A/en unknown
- 2017-12-19 AU AU2017384471A patent/AU2017384471B2/en active Active
- 2017-12-19 AR ARP170103569A patent/AR110394A1/es unknown
- 2017-12-19 RU RU2019122648A patent/RU2769285C2/ru active
- 2017-12-19 BR BR112019010903-0A patent/BR112019010903A2/pt unknown
- 2017-12-19 UA UAA201906847A patent/UA126025C2/uk unknown
-
2019
- 2019-06-11 PH PH12019501319A patent/PH12019501319A1/en unknown
- 2019-06-11 CO CONC2019/0006073A patent/CO2019006073A2/es unknown
- 2019-06-12 IL IL267287A patent/IL267287A/en unknown
- 2019-06-12 ZA ZA2019/03810A patent/ZA201903810B/en unknown
- 2019-06-19 CL CL2019001715A patent/CL2019001715A1/es unknown
- 2019-07-19 EC ECSENADI201951912A patent/ECSP19051912A/es unknown
-
2021
- 2021-02-10 US US17/172,109 patent/US11807680B2/en active Active
-
2023
- 2023-11-06 US US18/502,188 patent/US12473355B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020511946A5 (enExample) | ||
| JP2022191383A5 (enExample) | ||
| JP2024109678A5 (enExample) | ||
| IL276830B2 (en) | Anti-claudin 18.2 antibodies and uses thereof | |
| JP2020505386A5 (enExample) | ||
| JP2018521691A5 (enExample) | ||
| JP2009519718A5 (enExample) | ||
| JP2023093753A5 (enExample) | ||
| JP2014500009A5 (enExample) | ||
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2015514110A5 (enExample) | ||
| HRP20240413T1 (hr) | Antitijela za neutralizaciju poliomavirusa | |
| RU2012112829A (ru) | Анти-gitr-антитела | |
| JP2016538876A5 (enExample) | ||
| JP2019522961A5 (enExample) | ||
| JP2017505125A5 (enExample) | ||
| JPWO2019173291A5 (enExample) | ||
| JP2013543384A5 (enExample) | ||
| JP2012532851A5 (enExample) | ||
| JP2016520595A5 (enExample) | ||
| JP2017512759A5 (enExample) | ||
| RU2019122648A (ru) | Кристаллическая структура гремлин-1 и ингибирующее антитело | |
| JP2020515277A5 (enExample) | ||
| JP2020522280A5 (enExample) | ||
| RU2019139093A (ru) | Фармацевтическая композиция на основе антитела к pd-l1 и ее применение |